LIGAND PHARMA (LGDN BE) stock market data APIs
€166.3115
0(0%)
as of December 23, 2025
Try our APIs with
free plan!
LIGAND PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for LGDN.BE.
Prev. Close
166.3115
Open
166.3115
High
166.3115
Low
166.3115
52 wk Range
85.5-181
Market Cap
2 130 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get LIGAND PHARMA data using free add-ons & libraries
Get LIGAND PHARMA Fundamental Data
LIGAND PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LIGAND PHARMA News
New
3 Stocks Estimated To Be Up To 36.7% Below Intrinsic Value Offering Potential Opportunities
In recent market developments, the S&P 500 and Dow Jones Industrial Average have experienced declines following a surprising rise in unemployment, while the Nasdaq managed to tick higher, breaking its...
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Most readers would already be aware that Ligand Pharmaceuticals' (NASDAQ:LGND) stock increased significantly by 16% over the past three months. However, we wonder if the company's inconsistent financi...
LGND: 2025 Analyst Day
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day on December 9th, 2025, at the Harvard Club in New York ...
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Pharmaceuticals Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 mill...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
